Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Mike, please go ahead. Good morning, thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, Senior Vice President of Investor Relations. Joining me on today's ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In an era where financial literacy is increasingly recognized as a crucial ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. Ken Fisher is the founder and executive chairman of Fisher Asset Management ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. Ken Fisher is the founder and executive chairman of Fisher Asset Management, a ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...